Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 103 (2), 533-5

Ifosfamide and Vinorelbine: An Active Regimen for Patients With Relapsed or Refractory Hodgkin's Disease

Affiliations
Clinical Trial

Ifosfamide and Vinorelbine: An Active Regimen for Patients With Relapsed or Refractory Hodgkin's Disease

V Bonfante et al. Br J Haematol.

Abstract

Twenty-six patients with relapsed or refractory Hodgkin's disease (HD) were treated with an intensive salvage regimen combining ifosfamide (3000 mg/m2/d, days 1-4 through continuous intravenous infusion) and vinorelbine (25 mg/m2, i.v. days 1 and 5) with mesna uroprotection and G-CSF support. Courses were given at 3-week intervals. Ten patients achieved a complete and 10 patients a partial response, yielding an overall response rate of 77%. The main toxic effect was neutropenia and the combination was well tolerated.

Similar articles

See all similar articles

Cited by 3 PubMed Central articles

Publication types

Feedback